The most recent progress in this precedent is the administration of those radiotheranostic agents which target somatostatin receptors (SSTRs) in neuroendocrine tumours (NETs), human epidermal growth factor receptor 2 (HER2) antigens in BC and the prostate specific membrane antigen (PSMA) in prostate cancer (PC) [30,34,35]. This evidence concerns the gene ERBB2 and pachyonychia congenita.